Afzali A, Ulianov O, Eckardt L, Stas I, Seeholzer L, Steiger K
Acta Neuropathol Commun. 2025; 13(1):27.
PMID: 39934927
PMC: 11817536.
DOI: 10.1186/s40478-025-01947-8.
Preziosa P, Amato M, Battistini L, Capobianco M, Centonze D, Cocco E
J Neurol. 2024; 271(7):3879-3896.
PMID: 38771385
DOI: 10.1007/s00415-024-12426-w.
Amano E, Sato W, Kimura Y, Kimura A, Lin Y, Okamoto T
Neurol Neuroimmunol Neuroinflamm. 2024; 11(2):e200206.
PMID: 38350043
PMC: 11073873.
DOI: 10.1212/NXI.0000000000200206.
Kumpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Haussler V
J Neurol. 2023; 271(1):141-176.
PMID: 37676297
PMC: 10770020.
DOI: 10.1007/s00415-023-11910-z.
Zara P, Dinoto A, Carta S, Floris V, Turilli D, Budhram A
Eur J Neurol. 2023; 30(10):3367-3376.
PMID: 37433584
PMC: 10530555.
DOI: 10.1111/ene.15983.
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Aktas O, Hartung H, Smith M, Rees W, Fujihara K, Paul F
J Neurol Neurosurg Psychiatry. 2023; 94(9):757-768.
PMID: 37221052
PMC: 10447388.
DOI: 10.1136/jnnp-2022-330412.
A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder.
Berthele A, Levy M, Wingerchuk D, Pittock S, Shang S, Kielhorn A
Front Neurol. 2023; 14:1099376.
PMID: 37114235
PMC: 10126826.
DOI: 10.3389/fneur.2023.1099376.
MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity.
Yandamuri S, Filipek B, Obaid A, Lele N, Thurman J, Makhani N
JCI Insight. 2023; 8(11).
PMID: 37097758
PMC: 10393237.
DOI: 10.1172/jci.insight.165373.
White blood cell count profiles in anti-aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder and anti-myelin oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T, Misu T, Fujihara K, Nakaya K, Nakaya N, Nakamura T
Sci Rep. 2023; 13(1):6481.
PMID: 37081126
PMC: 10119079.
DOI: 10.1038/s41598-023-33827-3.
Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
Jarius S, Aktas O, Ayzenberg I, Bellmann-Strobl J, Berthele A, Giglhuber K
J Neurol. 2023; 270(7):3341-3368.
PMID: 37022481
PMC: 10267280.
DOI: 10.1007/s00415-023-11634-0.
Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesis.
Ponleitner M, Rommer P
Wien Med Wochenschr. 2022; 174(1-2):4-15.
PMID: 36472724
PMC: 10810999.
DOI: 10.1007/s10354-022-00987-2.
Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD.
Fadda G, Flanagan E, Cacciaguerra L, Jitprapaikulsan J, Solla P, Zara P
Front Neurol. 2022; 13:1011579.
PMID: 36419536
PMC: 9676369.
DOI: 10.3389/fneur.2022.1011579.
Neuromyelitis Optica Spectrum Disorder: From Basic Research to Clinical Perspectives.
Huang T, Wang J, Chang P, Hsu Y, Lin C, Lin K
Int J Mol Sci. 2022; 23(14).
PMID: 35887254
PMC: 9323454.
DOI: 10.3390/ijms23147908.
Relatively Early and Late-Onset Neuromyelitis Optica Spectrum Disorder in Central China: Clinical Characteristics and Prognostic Features.
Yu J, Yan S, Niu P, Teng J
Front Neurol. 2022; 13:859276.
PMID: 35493805
PMC: 9046694.
DOI: 10.3389/fneur.2022.859276.
The contribution of neuropathology to multiple sclerosis research.
Lassmann H
Eur J Neurol. 2022; 29(9):2869-2877.
PMID: 35427431
PMC: 9544263.
DOI: 10.1111/ene.15360.
Glial Fibrillary Acidic Protein in Blood as a Disease Biomarker of Neuromyelitis Optica Spectrum Disorders.
Kim H, Lee E, Lim Y, Kim K
Front Neurol. 2022; 13:865730.
PMID: 35370870
PMC: 8968934.
DOI: 10.3389/fneur.2022.865730.
Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
Redenbaugh V, Flanagan E
Neurotherapeutics. 2022; 19(3):808-822.
PMID: 35267170
PMC: 9294102.
DOI: 10.1007/s13311-022-01206-x.
Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.
Demuth S, Guillaume M, Bourre B, Ciron J, Zephir H, Sirejacob Y
J Neuroinflammation. 2022; 19(1):62.
PMID: 35236386
PMC: 8892703.
DOI: 10.1186/s12974-022-02420-2.
A new form of axonal pathology in a spinal model of neuromyelitis optica.
Herwerth M, Kenet S, Schifferer M, Winkler A, Weber M, Snaidero N
Brain. 2022; 145(5):1726-1742.
PMID: 35202467
PMC: 9166560.
DOI: 10.1093/brain/awac079.
Anterior optic pathway pathology in CNS demyelinating diseases.
Pisa M, Pansieri J, Yee S, Ruiz J, Leite M, Palace J
Brain. 2022; 145(12):4308-4319.
PMID: 35134111
PMC: 9762948.
DOI: 10.1093/brain/awac030.
